Zacks Investment Research downgraded shares of Aldeyra Therapeutics (NASDAQ:ALDX) from a buy rating to a hold rating in a research report released on Tuesday.
According to Zacks, “Aldeyra Therapeutics, Inc. is a biotechnology company. The company’s products target immune-mediated, inflammatory, orphan, and other diseases. It is developing NS2, a compound that binds and traps free aldehydes. Aldeyra Therapeutics, Inc. is based in Burlington, Massachusetts. “
ALDX has been the subject of several other research reports. ValuEngine raised shares of Aldeyra Therapeutics from a strong sell rating to a sell rating in a research note on Tuesday, September 12th. Canaccord Genuity reiterated a buy rating and issued a $27.00 target price (up from $12.00) on shares of Aldeyra Therapeutics in a report on Wednesday, September 13th. Cantor Fitzgerald started coverage on shares of Aldeyra Therapeutics in a report on Tuesday, October 24th. They issued an overweight rating and a $22.00 target price on the stock. Finally, Cowen reiterated an outperform rating and issued a $14.00 target price (up from $9.00) on shares of Aldeyra Therapeutics in a report on Thursday, September 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of Buy and a consensus target price of $17.29.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.09. equities analysts expect that Aldeyra Therapeutics will post -1.39 earnings per share for the current year.
A number of large investors have recently bought and sold shares of ALDX. 683 Capital Management LLC boosted its holdings in Aldeyra Therapeutics by 59.1% in the 3rd quarter. 683 Capital Management LLC now owns 835,514 shares of the biotechnology company’s stock valued at $6,016,000 after purchasing an additional 310,421 shares during the last quarter. Sphera Funds Management LTD. boosted its holdings in Aldeyra Therapeutics by 31.0% in the 2nd quarter. Sphera Funds Management LTD. now owns 875,931 shares of the biotechnology company’s stock valued at $4,117,000 after purchasing an additional 207,431 shares during the last quarter. Perceptive Advisors LLC boosted its holdings in Aldeyra Therapeutics by 6.9% in the 3rd quarter. Perceptive Advisors LLC now owns 3,085,458 shares of the biotechnology company’s stock valued at $22,215,000 after purchasing an additional 200,000 shares during the last quarter. Hikari Power Ltd lifted its holdings in shares of Aldeyra Therapeutics by 186.4% in the 2nd quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after acquiring an additional 70,196 shares during the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of Aldeyra Therapeutics in the 1st quarter worth approximately $132,000. Institutional investors own 47.89% of the company’s stock.
WARNING: “Aldeyra Therapeutics (ALDX) Downgraded to “Hold” at Zacks Investment Research” was originally published by Week Herald and is the property of of Week Herald. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://weekherald.com/2017/12/27/aldeyra-therapeutics-aldx-downgraded-to-hold-at-zacks-investment-research.html.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.